In a new clinical trial that could affect Hodgkin lymphoma (HL) treatments, researchers have reported a 92 percent survival rate among advanced-stage patients receiving a new immunotherapy regimen, potentially eliminating the need for radiation therapy and reducing long-term side effects commonly associated with traditional treatments.
This development marks a significant advancement in the fight against a type of cancer that predominantly affects younger people and those over 65.
Study Overview and Participant Diversity
Published in the New England Journal of Medicine on Wednesday, the trial indicates a potential shift in standard care for this rare but often deadly form of blood cancer.
Researchers enrolled nearly 1,000 patients from various cancer clinics and academic institutions across the United States and Canada. A key aspect of the trial was its inclusiveness: One-third of the participants were pediatric patients aged 12 and older, with 10 percent over 60. A quarter of the participants came from underrepresented demographics, addressing ongoing disparities in cancer treatment access and outcomes.
Participants were split into two groups: one received the standard treatment of chemotherapy with brentuximab vedotin, a drug that uses an antibody to deliver cancer-fighting medicine. The other group got the same treatment but also took nivolumab, a type of immunotherapy that helps the immune system target genetic changes linked to Hodgkin lymphoma. […]
— Read More: www.theepochtimes.com
-
Learn the TRUTH about Gold IRAs and how most precious metals companies play dirty.